Sygnature Discovery focuses on US expansion with the Appointment of Dr Bill Marathias
1st June 2018 – Nottingham, UK – Sygnature Discovery, the UK’s largest independent provider of integrated drug discovery resource and expertise, has appointed Dr Bill Marathias as Vice-President of Business Development for the USA to assist with the company’s ambitious international growth plans.
Sygnature Discovery already has a growing client base in the US, and is looking to expand this further. Bill will play an instrumental part of this expansion, working with colleague Dr Bruce Sargent, drawing on their combined experience and understanding of the US biopharmaceutical market.
Bill holds a Bachelor of Arts degree from Clark University (MA) and a Doctor of Philosophy degree in Chemistry from Wesleyan University (CT). Bill completed his Post-doctoral work at Massachusetts Institute of Technology (MIT), researching the structure and function of chemotherapeutic/drug-DNA/drug-protein interactions.
Bill has 18 years experience working in scientific and business development roles at Pfizer as a Senior Principal Scientist, at Agilent Technologies as a Senior Applications Scientist in Sales and Marketing, Head of Biophysics at Beryllium Discovery Corporation and as a National Director of Business Development at ChemPartner USA.
On his appointment, Bill commented: “I am proud to join Sygnature Discovery, particularly at such an exciting time in their business expansion plans. Sygnature is a highly respected research organization with a breadth of capability supported by substantial experience and truly integrated drug discovery services, which is rare in many contract research companies.”
He continued: “by establishing a strong USA market presence and by working closely with the Sygnature team in the UK, we will provide outstanding vaule to our USA clients research efforts”.
Founder and CEO of Sygnature Discovery, Dr Simon Hirst commented:
“Sygnature has always had clients in the USA since its foundation in 2004. However, to effectively develop even more business opportunities in North America, we need to expand our business development team so that we have a permanent presence there, situated in areas where cutting-edge drug discovery is taking place. We are delighted to welcome Bill to the team and having him ‘on the ground’ will boost our existing activities to win new clients across the US and support our ambitious expansion plans.”